Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
LG Chem will receive totaling up to $95.5 million for the China rights
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
Subscribe To Our Newsletter & Stay Updated
